bioAffinity Technologies, (NASDAQ: BIAF) saw its shares leap Wednesday, as the biotechnology company, developing noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, today announced publication of its research in high-throughput flow cytometry analysis of sputum. The journal PLOS ONE, published Sputum analysis by flow cytometry; an effective platform to analyze the lung environment reporting on results of analyzing sputum by flow cytometry as the basis for high-throughput diagnostic tests to determine the health of the lung.
“The PLOS ONE paper presents our unique method for determining the health of an individual’s lungs,” bioAffinity CEO Maria Zannes said.
“Flow cytometry allows for analysis of whole cells and cell populations that make up the lung environment. Our research provides a better understanding of how disease changes the lung environment and how flow cytometry can be used as a diagnostic tool by analyzing sputum.”
bioAffinity Technologies is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. The Company develops proprietary noninvasive diagnostic tests using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer.
The test is marketed as a Laboratory Developed Test by Precision Pathology Services. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.
BIAF shares grabbed $1.39, or 33.6%, to $5.53.
